Madrigal Pharmaceuticals, Inc. MDGL Net Income
Net Income at other companies
Segments
By segment
See fullOther financials
Where this comes from
Reported directly by Madrigal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Madrigal Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Madrigal Pharmaceuticals, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Madrigal Pharmaceuticals, Inc.'s net income?
- Madrigal Pharmaceuticals, Inc. (MDGL) reported net income of -$94.39M in Q1 2026.
- How has Madrigal Pharmaceuticals, Inc.'s net income changed year-over-year?
- Madrigal Pharmaceuticals, Inc.'s net income decreased by 28.9% year-over-year, from -$73.24M to -$94.39M.
- What is the long-term trend for Madrigal Pharmaceuticals, Inc.'s net income?
- Over 4 years (2021 to 2025), Madrigal Pharmaceuticals, Inc.'s net income has grown at a 4.5% compound annual growth rate (CAGR), from -$241.85M to -$288.28M.
- What does net income mean?
- The total profit or loss remaining after all company expenses are subtracted from total revenue.
- How do you interpret net income?
- An increase indicates improved profitability or reduced losses, while a decrease suggests rising costs or declining revenue generation.
- How does net income compare across companies?
- Biotech peers often report negative net income during high-growth R&D phases, with investors focusing on the burn rate relative to cash reserves.